Media

NewsMedia

CLIA Certificate of Compliance update

July 20, 2023
US clinical laboratory now fully accredited in 49 states Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that further to the RNS dated 2 March 2023, the Company has received compliance authorisation for the operation of its commercial clinical laboratory testing in respect of samples from an additional […]
Keep Reading

Successful validation of Clarava™ from an international clinical study

July 3, 2023
Clarava™, a first-in-class pre-transplant prognostic test for risk of early kidney rejection, On track for US commercial launch by end of 2023 Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces successful validation results from its prospective, blinded, international multi-centre clinical validation study for Clarava™. Clarava™, is the first pre-transplant prognostic test to […]
Keep Reading

Proposed US pricing for TutiviaTM

June 5, 2023
Medicare proposed gapfill median rate of $2,650 per test Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that a gapfill median rate of $2,650 has been proposed for TutiviaTM for kidney transplant rejection by the Centers for Medicare & Medicaid Services (“CMS”).Medicare is a national health insurance program […]
Keep Reading

2022 Annual Results

June 5, 2023
Successful transition from a research to commercial-stage company Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces its audited final results for the year ended 31 December 2022 and provides a progress update since year end. Strategic progress (including post-period end) Achieved full commercial launch of TutiviaTM, the Company’s […]
Keep Reading

Operational Update

March 22, 2023
First revenues from Tutivia™ following full commercial launch Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, provides an update on its operational progress made since the release of its interim results in September 2022.Verici Dx continues to execute the commercial introduction of Tutivia™, the Company’s first product for kidney […]
Keep Reading

Statement re. Silicon Valley Bank

March 13, 2023
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, is aware of public statements and media reports relating to Silicon Valley Bank (“SVB”). The Company does not hold any cash at SVB nor does it have any banking relationship with SVB.   Enquiries: Verici Dx is a developer of a […]
Keep Reading

Two key patents for Tutivia™ and Clarava™ granted in the United States

March 9, 2023
Intellectual property portfolio strengthened Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has been granted two key patents in the United States that support and protect the Company’s core technologies in RNA signature biomarker tests used for assessment of the prognostic risk pre-transplant (Clarava™) and post- […]
Keep Reading

Verici Dx achieves CLIA Certificate of Compliance for full commercial launch of Tutivia™

March 2, 2023
Successful CMS review and inspection solidify commercial positioning and represents a major milestone toward US Medicare reimbursement   Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it has successfully progressed its Registration status to Compliance Certification by the Centers for Medicare & Medicaid (“CMS’) for its commercial clinical operations to […]
Keep Reading

Vox Markets

November 3, 2022
Enjoy this informative interview with Paul Hill from Vox Markets, along with Sara Barrington and Barbara Murphy from Verici Dx. In it they discuss the function of the kidneys, What Verici Dx is, and much more.
Keep Reading

BRR Media

November 3, 2022
In this interview, Sara Barrington, CEO of Verici Dx, is joined by BRR Media to discuss the background of Verici Dx and where the company is moving towards in the future.
Keep Reading
1 2 3 … 7
crossmenuchevron-down